Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche, Generic Firms Offer SMART-er Accutane Risk Management Plan

Executive Summary

Roche and generic manufacturers' "consensus proposal" for additional Accutane (isotretinoin) risk management strategies will include mandatory patient and physician registries

You may also be interested in...



SMART-er Isotretinoin Risk Management Program To Be Operated By Covance

Covance will develop and operate a single, enhanced risk management program for all four isotretinoin products

Accutane Scripts Would Be Limited To Approved Indication Under House Bill

Prescriptions for Roche's Accutane would be limited to the acne drug's approved indication under legislation introduced June 16 by Reps. Bart Stupak (D-Mich.) and Chris Smith (R-N.J.)

Accutane Scripts Would Be Limited To Approved Indication Under House Bill

Prescriptions for Roche's Accutane would be limited to the acne drug's approved indication under legislation introduced June 16 by Reps. Bart Stupak (D-Mich.) and Chris Smith (R-N.J.)

Related Content

UsernamePublicRestriction

Register

PS043408

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel